All In Biotech

Drug Trial Radar · NCT07885917

Long-Term Safety and Tolerability of Nizubaglustat in Participants With Rare Lysosomal Disorders

An Open-label, Roll-over Trial to Evaluate the Long-term Safety and Tolerability of Nizubaglustat (AZ-3102) in Participants With Rare Lysosomal Disorders Who Have Participated in Previous Nizubaglustat Trials and Wish to Continue Nizubaglustat Treatment

Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

218

Planned (sponsor's estimate)

Start

Dec 10, 2026

Primary completion

Apr 1, 2030

Study completion Apr 1, 2030

Sponsor

Lead sponsor
Azafaros B.V.Industry
Sponsor type
Industry
First posted
Oct 21, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 4 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label extension trial to evaluate the long-term safety and tolerability of nizubaglustat (AZ-3102) in participants with rare lysosomal disorders who have participated in a previous nizubaglustat trial and wish to continue nizubaglustat treatment.

Conditions

  • Niemann-Pick Disease Type C
  • GM2 Gangliosidosis
  • GM1 Gangliosidosis
  • Gaucher Disease Type 3

Interventions

  • AZ-3102Drug

    Daily oral intake of nizubaglustat (AZ-3102) dispersible tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Incidence and severity of treatment-emergent adverse events (TEAEs)Time frame: Through study completion, an average of 4 years
  2. The Incidence and severity of treatment-emergent adverse events (TEAEs)Time frame: Through study completion, an average of 4 years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.